TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin

Cell Cycle

Volumn 11, Issue 15, 2012, Pages 2922-2930

  Yang, Nuo ^a   Morrison, Carl D ^a   Liu, Peijun ^b   Miecznikowski, Jeff ^a   Bshara, Wiam ^a   Han, Suxia ^b   Zhu, Qing ^b   Omilian, Angela R ^a   Li, Xu ^b   Zhang, Jianmin ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Amphiregulin (AREG); Epithelial to mesenchymal transition (EMT); Hippo pathway; TAZ; Tumor metastasis

Indexed keywords

AGAR; AMPHIREGULIN; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; TAZ PROTEIN; UNCLASSIFIED DRUG; YAP PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL; CANCER CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EFFECTOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MALIGNANT TRANSFORMATION; METASTASIS; PHENOTYPE; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN SECRETION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 84864541239     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21386     Document Type: Article

References (43)

1. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491-505; PMID:20951342; http://dx.doi.org/10.1016/j.devcel.2010.09.011.
2. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13:877-83; PMID:21808241; http://dx.doi.org/10.1038/ncb2303.
3. Mauviel A, Nallet-Staub F, Varelas X. Integrating developmental signals: a Hippo in the (path)way. Oncogene 2012; 31:1743-56; PMID:21874053; http://dx.doi.org/10.1038/onc.2011.363.
4. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28:2426-36; PMID:18227151; http://dx.doi.org/10.1128/MCB.01874-07.
5. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283:5496-509; PMID:18158288; http://dx.doi.org/10.1074/jbc.M709037200.
6. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010; 24:72-85; PMID:20048001; http://dx.doi.org/10.1101/gad.1843810.
7. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286:7018-26; PMID:21224387; http://dx.doi.org/10.1074/jbc.C110.212621.
8. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25:51-63; PMID:21205866; http://dx.doi.org/10.1101/gad.2000111.
9. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103:12405-10; PMID:16894141; http://dx.doi.org/10.1073/pnas.0605579103.
10. Gasparotto D, Polesel J, Marzotto A, Colladel R, Piccinin S, Modena P, et al. Overexpression of TWIST2 correlates with poor prognosis in head and neck squamous cell carcinomas. Oncotarget 2011; 2:1165-75; PMID:22201613.
11. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1:651-61; PMID:21317460.
12. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000; 19:6778-91; PMID:11118213; http://dx.doi.org/10.1093/emboj/19.24.6778.
13. Walter MA, Spillett DJ, Thomas P, Weissenbach J, Goodfellow PN. A method for constructing radiation hybrid maps of whole genomes. Nat Genet 1994; 7:22-8; PMID:8075634; http://dx.doi.org/10.1038/ng0594-22.
14. Mahoney WM Jr., Hong JH, Yaffe MB, Farrance IK. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J 2005; 388:217-25; PMID:15628970; http://dx.doi.org/10.1042/BJ20041434.
15. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001; 15:1229-41; PMID:11358867; http://dx.doi.org/10.1101/gad.888601.
16. Kitagawa M. A Sveinsson's chorioretinal atrophy-associated missense mutation in mouse Tead1 affects its interaction with the co-factors YAP and TAZ. Biochem Biophys Res Commun 2007; 361:1022-6; PMID:17689488; http://dx.doi.org/10.1016/j.bbrc.2007.07.129.
17. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22:1962-71; PMID:18579750; http://dx.doi.org/10.1101/gad.1664408.
18. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009; 284:13355-62; PMID:19324877; http://dx.doi.org/10. 1074/jbc.M900843200.
19. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474:179-83; PMID:21654799; http://dx.doi.org/10.1038/nature10137.
20. Cui CB, Cooper LF, Yang X, Karsenty G, Aukhil I. Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol 2003; 23:1004-13; PMID:12529404; http://dx.doi.org/10.1128/MCB.23.3.1004-1013. 2003.
21. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005; 309:1074-8; PMID:16099986; http://dx.doi.org/10.1126/science. 1110955.
22. Park KS, Whitsett JA, Di Palma T, Hong JH, Yaffe MB, Zannini M. TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J Biol Chem 2004; 279:17384-90; PMID:14970209; http://dx.doi.org/10.1074/jbc. M312569200.
23. Tian Y, Li D, Dahl J, You J, Benjamin T. Identification of TAZ as a binding partner of the polyomavirus T antigens. J Virol 2004; 78:12657-64; PMID:15507652; http://dx.doi .org/10.1128/JVI.78.22.12657-12664.2004.
24. Murakami M, Nakagawa M, Olson EN, Nakagawa O. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci USA 2005; 102:18034-9; PMID:16332960; http://dx.doi.org/10.1073/pnas.0509109102.
25. Murakami M, Tominaga J, Makita R, Uchijima Y, Kurihara Y, Nakagawa O, et al. Transcriptional activity of Pax3 is co-activated by TAZ. Biochem Biophys Res Commun 2006; 339:533-9; PMID:16300735; http://dx.doi.org/10.1016/j.bbrc.2005. 10.214.
26. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008; 10:837-48; PMID:18568018; http://dx.doi.org/10.1038/ncb1748.
27. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25:2594-609; PMID:22190458; http://dx.doi.org/10.1101/gad.176800.111.
28. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147:759-72; PMID:22078877; http://dx.doi.org/10.1016/j. cell.2011.09.048.
29. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005; 5:675-88; PMID:16148884; http://dx.doi.org/10.1038/nrc1695.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9.
31. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 2009; 11:1444-50; PMID:19935651; http://dx.doi.org/10.1038/ncb1993.
32. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 2011; 1816:119-31; PMID:21658434.
33. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 2010; 1:497-514; PMID:21165163.
34. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68:2592-8; PMID:18413727; http://dx.doi.org/10.1158/0008-5472.CAN-07-2696.
35. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21:2747-61; PMID:17974916; http://dx.doi.org/10.1101/gad.1602907.
36. Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res 2008; 68:2789-94; PMID:18413746; http://dx.doi.org/10.1158/0008-5472.CAN-07- 6205.
37. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFbeta-TrCP E3 ligase. J Biol Chem 2010; 285:37159-69; PMID:20858893; http://dx.doi.org/10.1074/jbc.M110.152942.
38. Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol 2006; 26:77-87; PMID:16354681; http://dx.doi.org/10.1128/MCB.26.1.77-87.2006.
39. Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K, et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci USA 2007; 104:1631-6; PMID:17251353; http://dx.doi.org/10.1073/pnas.0605266104.
40. Tian Y, Kolb R, Hong JH, Carroll J, Li D, You J, et al. TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol 2007; 27:6383-95; PMID:17636028; http://dx.doi.org/10.1128/MCB.00254-07.
41. Makita R, Uchijima Y, Nishiyama K, Amano T, Chen Q, Takeuchi T, et al. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol 2008; 294:F542-53; PMID:18172001; http://dx.doi.org/10.1152/ajprenal.00201.2007.
42. Booth BW, Boulanger CA, Anderson LH, Jimenez-Rojo L, Brisken C, Smith GH. Amphiregulin mediates self-renewal in an immortal mammary epithelial cell line with stem cell characteristics. Exp Cell Res 2010; 316:422-32; PMID:19913532; http://dx.doi.org/10.1016/j.yexcr.2009.11.006.
43. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30:256-68; PMID:12798140; http://dx.doi.org/10.1016/ S1046-2023(03)00032-X.